EDGAR HTML

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes included as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K to which this Operating and Financial Review and Prospects is attached, or the Form 6-K. The discussion below contains forward-looking statements (within the meaning of the United States federal securities laws) that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those identified in “Forward-Looking Statements and Factors that May Affect Future Results of Operations”, below, as well in the “Risk Factors” in Item 3.D of our Annual Report on Form 20-F for the year ended December 31, 2020, filed with the Securities and Exchange Commission, or SEC, on March 1, 2021, or our 2020 Annual Report.

We are a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. Leveraging distinct competitive advantages that include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, we are positioned to capture share in a significant and growing global marketplace, with a focus on manufacturing, which we view as having the largest and fastest growing total addressable market.

Our approximately 1,600 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, and education. Our products and comprehensive solutions improve product quality, development time, cost, and time-to-market. Our 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.

With our recent acquisition of Origin Laboratories, Inc., or Origin, we have significantly strengthened our leadership in mass production for polymer 3D printing. Origin’s pioneering approach to additive manufacturing of end-use parts will enable us to serve a large market with manufacturing-grade 3D printers, utilizing P³ Programmable PhotoPolymerization. This technology precisely controls light, heat, and force, among other variables, to produce parts with exceptional accuracy and consistency.

Our acquisition, in the first quarter of 2021, of UK-based RP Support Ltd., or RPS, a provider of industrial stereolithography 3D printers and solutions, provides us with a complementary technology that further expands our polymer suite of solutions across the product life cycle.

As in the preceding quarters, our results of operations for the three month period ended March 31, 2021 should be understood in light of the ongoing global COVID-19 pandemic, which has disrupted businesses on a global scale. Our revenues in the first quarter of 2021 reflected growth on a year-over-year basis relative to the first quarter of 2020, when we first began to experience the impact of the COVID-19 pandemic. This is the first quarter since the outset of the pandemic that we have achieved that year-over-year growth, primarily driven by a 40.9% increase in system revenues.

At the start of the first quarter of 2021, we eliminated our reduced four-day work-week, returning to a full work schedule for the first time since the second quarter of 2020. The proactive resizing measures we took in 2020 continued to succeed in reducing operating expenses during the first quarter, while our revenues have recovered and have retuned to growth on a year-over-year basis compared to the first quarter of 2020, when we first began to experience the effects of the pandemic in our operating results. We will continue to monitor and evaluate the need for our cost-control measures over time.

Our cost realignment program is an essential step in our ongoing strategic process, designed to better position the company for sustainable growth. These measures are not expected to affect the progress of our forthcoming product launch plans.

We continue to monitor the situation, assessing implications for our operations, supply chain, liquidity, cash flow and customer orders, and have been acting in an effort to mitigate adverse consequences as needed. We ended the first quarter of 2021 with $530.4 million in cash, cash equivalents and short-term deposits, following the net capital raise of $218.9 million. We believe that we are well suited to continue to manage the COVID-19 pandemic with a strong balance sheet and no debt, while focusing on cost controls and cash generation. We selectively applied the R&D cost controls to ensure that our NPI programs were not affected, and we plan to continue investing as needed in order to support our new product development programs.

Our unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. In the opinion of our management, all adjustments considered necessary for a fair statement of the unaudited condensed consolidated financial statements have been included herein and are of a normal recurring nature. The following discussion compares the actual results, on a GAAP basis, for the three months ended March 31, 2021 with the corresponding period in 2020.

Comparison of Three Months Ended March 31, 2021 to Three Months Ended March 31, 2020

The following table sets forth certain statement of operations data for the periods indicated:

	Three Months Ended March 31,
	2021					2020
		U.S. $ in thousands		% of Revenues			U.S. $ in thousands		% of Revenues
Revenues	$	134,189		100.0	%	$	132,907		100.0	%
Cost of revenues		78,612		58.6	%		73,037		55.0	%
Gross profit		55,577		41.4	%		59,870		45.0	%
Research and development, net		20,601		15.4	%		24,194		18.2	%
Selling, general and administrative		53,334		39.7	%		55,576		41.8	%
Operating loss		(18,358	)	(13.7	)%		(19,900	)	(15.0	)%
Financial expense		(377	)	(0.3	)%		(829	)	(0.6	)%
Loss before income taxes		(18,735	)	(14.0	)%		(20,729	)	(15.6	)%
Income tax expenses (benefit)		(942	)	(0.7	)%		221		0.2	%
Share in losses of associated companies		(1,118	)	(0.8	)%		(838	)	(0.6	)%
Net loss attributable to non-controlling interests		-		0.0	%		(85	)	(0.1	)%
Net loss attributable to Stratasys Ltd.		(18,911	)	(14.1	)%		(21,703	)	(16.3	)%

Our products and services revenues in the three months ended March 31 2021 and 2020, as well as the percentage change reflected thereby, were as follows:

Revenues derived from products (including AM systems and consumable materials) increased by $7.2 million, or 8.6%, for the three months ended March 31, 2021, as compared to the three months ended March 31, 2020.

System revenues for the three months ended March 31, 2021 increased by 40.9% as compared to the three months ended March 31, 2020. Consumables revenues for the three months ended March 31, 2021 decreased by 8.0% as compared to the three months ended March 31, 2020.

Our first quarter revenue results demonstrated continued recovery signs in system revenues. As the market recovers from COVID-19 and usage rates of our systems increases, a sequential growth in consumables should be followed through the balance of the year.

Services revenues (including SDM, maintenance contracts, time and materials and other services) decreased by $5.9 million for the three months ended March 31, 2021, or 11.8%, as compared to the three months ended March 31, 2020. Within services revenues, customer support revenue, which includes revenue generated mainly by maintenance contracts on our systems, decreased by 2.2%, reflecting lower printer utilization due to the effects of COVID-19.

Revenues and the percentage of revenues by region for the three months ended March 31, 2021 and 2020, as well as the percentage change in revenues in each such region reflected thereby, were as follows:

	Three Months Ended March 31,
	2021				2020				% Change
		U.S.$ in thousands	% of Revenues			U.S.$ in thousands	% of Revenues
Americas*	$	82,113	61.2	%	$	86,573	65.1	%	(5.2	)%
EMEA		28,918	21.6	%		26,920	20.3	%	7.4	%
Asia Pacific		23,158	17.2	%		19,414	14.6	%	19.3	%
	$	134,189	100.0	%	$	132,907	100.0	%	1.0	%

Revenues in the Americas region decreased by $4.5 million, or 5.2%, to $82.1 million for the three months ended March 31, 2021, compared to $86.6 million for the three months ended March 31, 2020. The decrease was primarily driven by lower consumables revenues and COVID-19 impact on some of our key industries, such as commercial Aerospace and Government.

Revenues in the EMEA region increased by $2.0 million, or 7.4%, to $28.9 million for the three months ended March 31, 2021, compared to $26.9 million for the three months ended March 31, 2020. The increase was primarily driven by higher products revenues, mainly in Manufacturing and Healthcare industries. On a constant currency basis when using prior period’s exchange rates, revenues decreased by $0.2 million, or 0.6%. The decrease was primarily driven by lower consumables revenues.

Revenues in the Asia Pacific region increased by $3.7 million, or 19.3%, to $23.2 million for the three months ended March 31, 2021, compared to $19.4 million for the three months ended March 31, 2020. The increase was primarily driven by higher products revenues.

Gross profit from our products and services, as well as the percentage change reflected thereby, was as follows:

Gross profit as a percentage of revenues from our products and services was as follows:

Gross profit attributable to products revenues decreased by $0.5 million, or 1.2%, to $43.4 million for the three months ended March 31, 2021, compared to gross profit of $43.9 million for the three months ended March 31, 2020. Gross profit attributable to products revenues as a percentage of products revenues decreased to 48.1% for the three months ended March 31, 2021, compared to 52.8% for the three months ended March 31, 2020. Our gross profit from products revenues was adversely impacted by the mix of revenue sources, partially offset by a favorable impact of foreign currencies translation.

Gross profit attributable to services revenues decreased by $3.8 million, or 23.7%, to $12.2 million for the three months ended March 31, 2021, compared to $15.9 million for the three months ended March 31, 2020. Gross profit attributable to services revenues as a percentage of services revenues in the three months ended March 31, 2021 decreased to 27.8%, as compared to 32.1% for the three months ended March 31, 2020. Our gross profit from services revenues was adversely impacted by softness in our direct manufacturing activity (SDM), which has a relatively high percentage of fixed costs.

The decrease in gross profit was primarily driven by the lower proportion of consumables, lower SDM contribution and an increased logistics costs.

The amount of each type of operating expense for the three months ended March 31, 2021 and 2020, as well as the percentage change reflected thereby, and total operating expenses as a percentage of our total revenues in each such quarter, were as follows:

	Three Months Ended March 31,
		2021			2020		% Change
	U.S. $ in thousands

Research and development, net	$	20,601		$	24,194		(14.9	)%
Selling, general & administrative		53,334			55,576		(4.0	)%
	$	73,935		$	79,770		(7.3	)%
Percentage of revenues		55.1	%		60.0	%

Operating expenses were $73.9 million in the first quarter of 2021, compared to operating expenses of $79.8 million in the first quarter of 2020. The decrease in operating expenses was driven by the resizing plan initiated in 2020.

Research and development expenses, net decreased by $3.6 million, or 14.9%, to $20.6 million for the three months ended March 31, 2021, compared to $24.2 million for the three months ended March 31, 2020. The amount of research and development expenses constituted 15.4% of our revenues for the three months ended March 31, 2021, as compared to 18.2% for the three months ended March 31, 2020.

Our research and development expenses were impacted by the timing of project spending and product launches, based on our portfolio management. We continue to invest in strategic long-term initiatives that include advancements in our core FDM and PolyJet technologies and in our new photopolymer-based P3 technology, advanced composite materials, software and development of new applications which will enhance our current solutions offerings. We selectively applied the R&D cost controls to ensure that our new product introduction programs were not affected, and we plan to continue investing as needed in order to support our new product development programs.

Selling, general and administrative expenses decreased by $2.2 million, or 4.0%, to $53.3 million for the three months ended March 31, 2021, compared to $55.6 million for the three months ended March 31, 2020, driven by the restructuring and proactive cost-cutting measures. The amount of selling, general and administrative expenses constituted 39.7% of our revenues for the three months ended March 31, 2021, as compared to 41.8% for the three months ended March 31, 2020.

Operating loss and operating loss as a percentage of our total revenues were as follows:

Operating loss amounted to $18.4 million for the three months ended March 31, 2021, compared to an operating loss of $19.9 million for the three months ended March 31, 2020. The decrease in operating loss was primarily attributable to the lower operating expenses as discussed above, offset, in part, by lower gross profit for the three months ended March 31, 2021 compared to the three months ended March 31, 2020.

Financial expenses, net, which was primarily comprised of foreign currencies effects, interest income and interest expenses, was $0.4 million for the three months ended March 31, 2021, compared to financial expense, net of $0.8 million for the three months ended March 31, 2020.

Income taxes and income taxes as a percentage of net loss before taxes, as well as the percentage change in each, year over year, reflected thereby, were as follows:

We had an effective tax rate of 5.0% for the three-month period ended March 31, 2021, compared to a negative effective tax rate of 1.1% for the three-month period ended March 31, 2020. Our effective tax rate was primarily impacted by different geographic mixes of earnings and losses, as well as a valuation allowance on losses of our US subsidiaries.

Share in losses of associated companies reflects our proportionate share of the losses of unconsolidated entities accounted for by using the equity method of accounting. During the three months ended March 31, 2021, the loss from our proportionate share of the losses of our equity method investments was $1.1 million, compared to a loss of $0.8 million in the three months ended March 31, 2020.

Net loss attributable to Stratasys Ltd., and net loss per share were as follows:

	Three Months Ended March 31,
		2021			2020
	U.S. $ in thousands

Net income (loss) attributable to Stratasys Ltd.	$	(18,911	)	$	(21,703	)

Percentage of revenues		(14.1	)%		(16.3	)%

Diluted net (loss) income per share	$	(0.32	)	$	(0.40	)

Net loss attributable to Stratasys Ltd. was $18.9 million for the three months ended March 31, 2021 compared to net loss of $21.7 million for the three months ended March 31, 2020. The decrease in the net loss attributable to Stratasys Ltd. was primarily attributable to the cost-mitigation measures, offset partially by lower gross profit, as described above.

Net loss per share was $0.32 for the three months ended March 31, 2021 as compared to net loss per share of $0.40 for the three months ended March 31, 2020. The weighted average fully diluted share count was 58.6 million during the three months ended March 31, 2021, compared to 54.5 million during the three months ended March 31, 2020.

The following non-GAAP data, which excludes certain items as described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures are useful information for investors and shareholders of our company in gauging our results of operations (i) on an ongoing basis after excluding mergers, acquisitions and divestments related expense or gains and restructuring-related charges or gains, and (ii) excluding non-cash items such as stock-based compensation expenses, acquired intangible assets amortization, including intangible assets amortization related to equity method investments, impairment of long-lived assets and goodwill, revaluation of our investments and the corresponding tax effect of those items. These non-GAAP adjustments either do not reflect actual cash outlays that impact our liquidity and our financial condition or have a non-recurring impact on the statement of operations, as assessed by management. These non-GAAP financial measures are presented to permit investors to more fully understand how management assesses our performance for internal planning and forecasting purposes. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all items indicated above during a period, which may not provide a comparable view of our performance to other companies in our industry. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with GAAP. Reconciliation between results on a GAAP and non-GAAP basis is provided in a table below.

The following tables present the GAAP measures, the corresponding non-GAAP amounts and the related non-GAAP adjustments for the applicable periods:

	Three Months Ended March 31,
		2021			2020
	U.S $ in thousands
Net loss	$	(18,911	)	$	(21,788	)
Depreciation and amortization		13,802			12,457
Deferred income taxes		(1,774	)		(409	)
Stock-based compensation		7,205			4,907
Other non-cash items, net		1,822			4,467
Change in working capital and other items		20,607			11,640
Net cash provided by operating activities		22,751			11,274
Net cash used in investing activities		(92,744	)		(5,498	)
Net cash provided by financing activities		222,165			30
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(2,872	)		(2,116	)
Net change in cash, cash equivalents and restricted cash		149,300			3,690
Cash, cash equivalents and restricted cash, beginning of period		272,216			293,597
Cash, cash equivalents and restricted cash, end of period		421,516			297,287

Our cash, cash equivalents and restricted cash balance increased to $421.5 million as of March 31, 2021 from $272.2 million as of December 31, 2020. The increase in cash, cash equivalents and restricted cash in the three months ended March 31, 2021 was primarily due to the public offering of shares in a net amount of $218.9 million, partially offset by investing activities.

We generated $22.8 million of cash from operating activities during the three months ended March 31, 2021. That cash generation reflects our $18.9 million net loss, as adjusted upwards to eliminate non-cash charges included in net loss, $13.8 million of depreciation and amortization and $7.2 million of stock-based compensation expenses. Favorable changes in our working capital balances were mainly driven by a decrease in our accounts receivable and inventory balances, and an increase in our accounts payable balance.

We used $92.7 million of cash in our investing activities during the three months ended March 31, 2021. Cash was primarily used to invest $4.3 million to purchase property, equipment and intangibles, and $82.0 million net investment in short-term bank deposits. Our principal property and equipment purchases were for our new buildings complex under construction in Rehovot, Israel. The new facility in Rehovot, Israel, which will contain two buildings, houses our Israeli headquarters, research and development facilities and certain marketing activities. In addition, we used $6.4 million of cash for acquisitions, net of cash acquired.

We generated $222.2 million of cash from financing activities during the three months ended March 31, 2021. Our public offering of shares generated proceeds, net of issuance costs of $218.9 million, and we generated an additional $2.9 million of proceeds from exercise of stock options.

Our total current assets amounted to $784.5 million as of March 31, 2021, of which $530.5 million consisted of cash, cash equivalents, short-term deposits and restricted cash. Total current liabilities amounted to $146.6 million. Most of our cash and cash equivalents are held in banks in Israel and the U.S.

The credit risk related to our accounts receivable is limited due to the relatively large number of customers and their wide geographic distribution. In addition, we seek to reduce the credit exposure related to our accounts receivable by imposing credit limits, conducting ongoing credit evaluation, and by implementing account monitoring procedures, as well as credit insurance for many of our customers.

We believe that we will have adequate cash and cash equivalents to fund our ongoing operations and that these sources of liquidity will be sufficient to satisfy our capital expenditure and working capital needs for the next twelve months.

We have prepared our consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America. This has required us to make estimates, judgments, and assumptions that affected the amounts we reported. Actual results may differ from those estimates. To facilitate the understanding of our business activities, certain accounting policies that are important to the presentation of our financial condition and results of operations and that require management’s subjective judgments are described in our 2020 Annual Report. We base our judgments on our experience and various assumptions that we believe to be reasonable under the circumstances.

Forward-Looking Statements and Factors That May Affect Future Results of Operations

Certain information included in or incorporated by reference into the Report of Foreign Private Issuer on Form 6-K to which this Operating and Financial Review is appended, or the Form 6-K, may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those that predict or describe future events or trends and that do not relate solely to historical matters. You can generally identify forward-looking statements as statements containing the words “may,” “will,” “could,” “should,” “expect,” “anticipate,” “intend,” “estimate,” “believe,” “project,” “plan,” “assume” or other similar expressions, or negatives of those expressions, although not all forward-looking statements contain these identifying words.

These forward-looking statements may include, but are not limited to, statements regarding our future strategy, future operations, projected financial position, proposed products, estimated future revenues, projected costs, future prospects, the future of our industry and results that might be obtained by pursuing management’s current plans and objectives.

You should not place undue reliance on our forward-looking statements because the matters they describe are subject to certain risks, uncertainties and assumptions that are difficult to predict. Our forward-looking statements are based on the information currently available to us and speak only as of the date of the Form 6-K. Over time, our actual results, performance or achievements may differ from those expressed or implied by our forward-looking statements, and such difference might be significant and materially adverse to our shareholders. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:

the extent of our success at introducing new or improved products and solutions that gain market share;

the duration and severity of the global COVID-19 pandemic, and the strength of recovery from it, which may continue to have significant consequences for our operations, financial position, cash flows, and those of our customers and suppliers;

changes in our overall strategy, including as related to any restructuring activities and our capital expenditures;

the impact of shifts in prices or margins of the products that we sell or services we provide;

impairments of goodwill or other intangible assets in respect of companies that we acquire;

the extent of our success at efficiently and successfully integrating the operations of various companies that we have acquired or may acquire;

global market, political and economic conditions, and in the countries in which we operate in particular;

infringement of our intellectual property rights by others (including for replication and sale of consumables for use in our systems), or infringement of others’ intellectual property rights by us;

• the extent of our success at maintaining our liquidity and financing our operations and capital needs;

impact of tax regulations on our results of operations and financial conditions; and

those factors referred to in Item 3.D, “Key Information - Risk Factors”, Item 4, “Information on the Company”, and Item 5, “Operating and Financial Review and Prospects” in our 2020 Annual Report, as supplemented herein, as well as in other portions of the 2020 Annual Report

Readers are urged to carefully review and consider the various disclosures made throughout the Form 6-K, our 2020 Annual Report, and in our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Reference is made to Item 11, “Quantitative and Qualitative Disclosures about Market Risk” in our 2020 Annual Report.

We are subject to various litigation and other legal proceedings from time to time. For a discussion of our litigation status, see Note 12-“Contingencies” in the notes to our unaudited condensed consolidated interim financial statements attached as Exhibit 99.1 to the Form 6-K.

The global COVID-19 health pandemic has been adversely affecting and could potentially severely adversely affect, our business, results of operations and financial condition due to impacts on the industries in which our customers operate, as well as impacts from actions taken to contain the disease or treat its impact, and due to the unknown speed and extent of the recovery from the disease.

The COVID-19 global pandemic continues to have numerous adverse effects on the global economy. Governmental shutdowns and “shelter-in-place” orders suggested or mandated by governmental authorities or otherwise elected by companies as a preventative measure, continue to adversely affected workforces, customers, consumer sentiment, economies and certain financial markets, and, along with decreased consumer spending, have led to an economic downturn in many of the markets into which we sell our products and services.

Those effects of the pandemic have been adversely impacting our financial results for our operations in all global regions, beginning already in the first quarter of 2020 and continuing through the first quarter of 2021.

While we have imposed counter-measures to try to mitigate the impact of the pandemic on our operating results and our results have shown improvement concurrently with recovery in some of the markets into which we sell, there is no certainty that the success of those measures and that recovery will continue. We continue to monitor the cost-control measures that we first began to implement in February 2020. We have maintained in place certain cost reduction mechanisms, although we have eliminated others, such as our four-day work week, as we returned to a full work week, effective as of the start of 2021.

While we continue to monitor the situation, assessing further implications for our operations, supply chain, liquidity, cash flow and customer orders, and have implemented the foregoing measures in an effort to mitigate adverse consequences, while simultaneously abiding by any government-imposed restrictions, market by market, there is no assurance that we can succeed at doing so.

In addition to the adverse impact of the COVID-19 pandemic on our business and operating results, we furthermore face uncertainty as to the degree and duration of that impact going forward, and as to the degree of recovery from it. We do not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, and the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic. The pandemic may furthermore contribute towards global economic weakness that is more than temporary and that could adversely affect demand for our products and services generally. A future downturn could also have a material adverse impact on our business partners’ stability and financial strength. Given the uncertainties associated with COVID-19, it is difficult to fully predict the magnitude of effects on our, and our business partners’, business, financial condition and results of operations.


		Three Months Ended March 31,
			2021			Non-GAAP			2021			2020			Non-GAAP			2020
			GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP
		U.S. dollars and shares in thousands (except per share amounts)
	Gross profit (1)	$	55,577		$	7,069		$	62,646		$	59,870		$	4,414		$	64,284
	Operating income (loss) (1,2)		(18,358	)		15,785			(2,573	)		(19,900	)		11,491			(8,409	)
	Net income (loss) attributable to Stratasys Ltd. (1,2,3)		(18,911	)		15,111			(3,800	)		(21,703	)		11,137			(10,566	)
	Net income (loss) per diluted share attributable to Stratasys Ltd. (4)	$	(0.32	)	$	0.26		$	(0.06	)	$	(0.40	)	$	0.21		$	(0.19	)


(1)	Acquired intangible assets amortization expense					5,356									4,065
	Non-cash stock-based compensation expense					634									402
	Restructuring and other related costs					1,079									(53	)
						7,069									4,414

(2)	Acquired intangible assets amortization expense					2,192									2,142
	Non-cash stock-based compensation expense					6,571									4,503
	Restructuring and other related costs					1,810									31
	Revaluation of investments					(3,670	)								-
	Contingent consideration					191									-
	Other expenses					1,622									401
						8,716									7,077
						15,785									11,491

(3)	Corresponding tax effect					(757	)								(431	)
	Equity method related amortization, divestments and impairments					83									77
					$	15,111								$	11,137

(4)	Weighted average number of ordinary shares outstanding- Diluted		58,616						58,616			54,544						54,544